摘要
目的 幽门螺杆菌(Hp)感染是引起消化系统疾病的主要原因之一，采用四联疗法进行治疗，并分析其应用效果。方法 将2020年1月-2022年3月期间我院及进修学习期间收治的158例幽门螺杆菌(Hp)感染患者随机分为对照组和实验组，各79例，对照组采用三联疗法，实验组为四联疗法，对比应用效果。结果 实验组幽门螺旋杆菌清除率高于对照组，且不良反应发生率低于对照组，对比两组临床症状积分，实验组优于对照组，P＜0.05。结论 四联疗法能够更加高效的清除HP，改善患者的临床症状，对患者的消化道进行保护，可以使不良反应的发生率降低，在患者治疗期间保证安全性，更加快速的缓解患者的临床症状。
关键词： 四联疗法；幽门螺杆菌；感染；不良反应
Abstract
Objective: Helicobacter pylori (HP) infection is one of the main causes of digestive system diseases. Four combination therapy is used for treatment, and its application effect is analyzed. Methods: 158 patients with Helicobacter pylori (HP) infection treated in our hospital from January 2020 to December 2021 were randomly divided into control group and experimental group, with 79 cases in each group. The control group was treated with triple therapy and the experimental group was treated with quadruple therapy. The application effects were compared. Results: the clearance rate of Helicobacter pylori in the experimental group was higher than that in the control group, and the incidence of adverse reactions was lower than that in the control group ，comparing the two groups, the experimental group was better than the control group,(P < 0.05). Conclusion : quadruple therapy can remove HP more efficiently, improve patients' clinical symptoms, protect patients' digestive tract, reduce the incidence of adverse reactions, ensure safety during patients' treatment, and alleviate patients' clinical symptoms more quickly.
Key words： Quadruple Therapy; Helicobacter Pylori; Infected; Adverse Reactions
参考文献 References
[1] 樊文静,张振宇,杨景玉,等.含铋剂四联疗法治疗幽门螺旋杆菌阳性胃溃疡的临床效果[J].广西医学,2019, 41(18): 2306-2308.
[2] 罗酩,吴永梅,李文娟,等.四联疗法对幽门螺杆菌相关性胃溃疡的疗效及对胃黏膜形态学的影响[J].山西医药杂志,2021,50(10):1698-1699.
[3] 刘宏伟,黄玉洁,杨剑英,等.含阿莫西林、呋喃唑酮四联疗法治疗幽门螺杆菌相关性胃溃疡的疗效及安全性分析[J].河北医药,2020,42(8):1169-1172.
[4] 郑思旸.埃索美拉唑四联疗法治疗对幽门螺杆菌感染胃溃疡患者炎症介质及胃肠激素的影响[J].医疗装备,2021, 34(23):118-119.
[5] 秦文羚,胡松,陈敏,等.雷贝拉唑与奥美拉唑四联疗法对Hp感染胃溃疡患者Hp根除率及炎性因子水平的影响[J].当代医学,2021,27(12):143-144.
[6] 童泽会,杨松.雷贝拉唑四联疗法对幽门螺杆菌感染治疗效果的影响[J].世界最新医学信息文摘,2021,21(61): 199-200.
[7] 周克建.四联疗法对幽门螺杆菌感染患者HP根除率及肠道菌群和炎症因子水平的影响[J].江西医药,2021, 56(12): 2310-2311,2320.
[8] 王永虎,曲志培.雷贝拉唑四联疗法对幽门螺杆菌相关性胃溃疡患者血清生长抑素、胃泌素及炎性因子的影响[J].中国医院用药评价与分析,2018,18(10):1375-1376,1380.
[9] 骆丽蓉.比较雷贝拉唑四联疗法、奥美拉唑四联疗法治疗幽门螺杆菌(Hp)相关性胃溃疡的价值[J].世界复合医学,2019,5(8):168-171.
[10] 陈兆夷,黄志刚,邓衍部,等.含铋剂四联疗法治疗慢性胃溃疡伴幽门螺杆菌感染患者的临床疗效研究[J].中华生物医学工程杂志,2019,25(6):763-767.